Autolus Therapeutics (NASDAQ:AUTL) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Autolus Therapeutics (NASDAQ:AUTL) had its price objective upped by analysts at Needham & Company LLC from $10.00 to $11.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 458.38% from the company’s current price.

Several other analysts also recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday, September 24th. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Autolus Therapeutics Trading Up 5.3%

NASDAQ AUTL opened at $1.97 on Monday. Autolus Therapeutics has a 1 year low of $1.11 and a 1 year high of $2.80. The company has a market cap of $524.30 million, a PE ratio of -2.37 and a beta of 2.01. The stock’s 50-day moving average price is $1.49 and its two-hundred day moving average price is $1.78.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The firm had revenue of $21.19 million during the quarter, compared to analysts’ expectations of $21.08 million. Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%. Research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently made changes to their positions in AUTL. Armistice Capital LLC increased its stake in shares of Autolus Therapeutics by 9.1% during the 2nd quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock worth $27,360,000 after purchasing an additional 1,000,000 shares during the last quarter. TFG Asset Management GP Ltd lifted its stake in shares of Autolus Therapeutics by 10.5% in the 2nd quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after purchasing an additional 900,000 shares during the last quarter. Cetera Investment Advisers boosted its holdings in Autolus Therapeutics by 17.6% in the second quarter. Cetera Investment Advisers now owns 617,172 shares of the company’s stock worth $1,407,000 after purchasing an additional 92,300 shares in the last quarter. Atle Fund Management AB increased its position in Autolus Therapeutics by 130.5% during the second quarter. Atle Fund Management AB now owns 1,105,461 shares of the company’s stock worth $2,520,000 after buying an additional 625,817 shares during the last quarter. Finally, Vident Advisory LLC bought a new position in Autolus Therapeutics during the first quarter valued at about $241,000. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.